Cara Therapeutics to Present at American Pain Society 34th Annual Scientific Meeting
May 06 2015 - 8:00AM
- Pain experts to discuss kappa opioid receptor agonists and
latest developments in pain management
- Company to present positive data from Phase 2, human abuse
liability studies of I.V. CR845 during poster sessions
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
kappa opioid receptors, today announced that it is sponsoring a
Town Hall Talk titled "Kappa Opioid Receptor Agonists (KORAs) –
Moving Beyond Mu" at the American Pain Society's 34th Annual
Scientific Meeting in Palm Springs, California. Leading experts
will discuss the scientific and clinical progress of a new class of
analgesics, kappa opioid receptor agonists (KORAs), and share data
from Cara's human abuse liability study of I.V. CR845, the
Company's first-in-class peripherally-selective kappa opioid
agonist which has potential to be the only Schedule V or
non-scheduled opioid for acute pain.
The Town Hall Talk details are as follows:
Date: Thursday, May 14,
2015 |
Time: 1:30 p.m. PT |
Location: Palm Springs
Convention Center, The Experience Exchange |
Experts: Lynn Webster, MD,
Vice President of Scientific Affairs at PRA International,
immediate past president, American Academy of Pain Medicine, and
Joseph Stauffer, DO, MBA, Chief Medical Officer, Cara
Therapeutics |
In addition, Cara will present two posters in author-attended
sessions. Both posters will remain on display throughout the
duration of the event, from Wednesday, May 13 through Friday, May
15.
Poster Title: "CR845, a
novel peripherally-acting kappa opioid receptor agonist, has low
abuse potential compared with pentazocine" |
Date: Thursday, May 14,
2015 |
Time: 9:30 – 11 a.m. PT |
Presenters: Lynn Webster,
MD, Vice President of Scientific Affairs at PRA International,
immediate past president, American Academy of Pain Medicine, and
Joseph Stauffer, DO, MBA, Chief Medical Officer, Cara
Therapeutics |
|
Poster Title: "CR845, a
peripheral kappa opioid, provides better pain relief with less
nausea and vomiting than placebo in patients after
bunionectomy" |
Date: Thursday, May 14,
2015 |
Time: 3:45 – 5:15 p.m.
PT |
Presenter: Robert Spencer,
Ph.D., Senior Director, Research & Development, Cara
Therapeutics, and Joseph Stauffer, DO, MBA, Chief Medical Officer,
Cara Therapeutics |
For more information about the American Pain Society's 34th
Annual Scientific Meeting, visit:
http://americanpainsociety.org/annual-meeting/upcoming-annual-meeting/overview.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist
currently in development for the treatment of acute and chronic
pain and uremic pruritus. In multiple randomized, double blind,
placebo-controlled Phase 2 trials in patients undergoing
laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845
treatment resulted in statistically significant reductions in pain
intensity and opioid-related side effects. In over 400 subjects
dosed to date, I.V. CR845 was found to be safe and well tolerated,
without incurring the dysphoric and psychotomimetic side effects
that have been reported with centrally acting (CNS-active) kappa
opioid receptor agonists. In a human abuse liability trial, I.V.
CR845 met the primary endpoint showing highly statistically
significant reductions (p < 0.0001) in scores for "drug liking,"
as well as "feeling high," "overall liking," and "take drug again"
when compared to I.V. pentazocine, a Schedule IV opioid
analgesic.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
kappa opioid receptors. Cara is developing a novel and proprietary
class of product candidates that target the body's peripheral
nervous system and have demonstrated efficacy in patients with
moderate-to-severe pain without inducing many of the undesirable
side effects typically associated with currently available pain
therapeutics.
CONTACT: INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jul 2023 to Jul 2024